AAV2-GDNF
Asset
AAV2 vector encoding GDNF delivered to the putamen for neurotrophic support
- Stage
- Phase 2
- Modality
- Gene therapy
- Target
- GDNF
- 1
- Indication
- 1
- Trial
- 1
- Developer
Indications
1Parkinson's disease
Phase 2, Active not recruiting, NCT06285643, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners2
- Trials1
- Evidence for its targets1
- Competitors1
- Aging relevance1
Every asset’s record: target, stage, trials and the evidence behind it.